Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Dose-Response Trial of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures, With Optional Open-Label Extension

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2019

At a glance

  • Drugs Cenobamate (Primary)
  • Indications Partial epilepsies
  • Focus Therapeutic Use
  • Sponsors SK Life Science
  • Most Recent Events

    • 27 Apr 2018 Primary endpoint (Percent reduction in seizure frequency) has been met, according to results presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 27 Apr 2018 Results (n=437) assessing efficacy of adjunctive cenobamate treatment for different types of partial-onset seizures, including simple partial motor (SPS), complex partial (CPS), and secondary generalized tonic-clonic (SGTC) seizures, were presented at the 70th Annual Meeting of the American Academy of Neurology.
    • 23 Apr 2018 Cross-checked for the study reported in MR 9238715 source with the abstracts presented at Academy of Neurology Annual Meeting (AAN) and identified this as the correct match.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top